TTrialPathMatch Me to Trials
← Back to trials
RecruitingOverweightObesity

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Eligible age

18–55 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Sponsor: Novo Nordisk A/S

You may qualify if…

  • ✓ Male or female (sex at birth).
  • ✓ Age 18-55 years (both inclusive) at the time of signing informed consent.
  • ✓ Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
  • ✓ Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

You may not qualify if…

  • ✕ Known or suspected hypersensitivity to study intervention(s) or related products.
  • ✕ Previous randomisation in this study.
  • ✕ History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
  • ✕ Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
  • ✕ Current participation (signed informed consent) in any other interventional clinical study.
  • ✕ Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
  • ✕ Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
  • ✕ Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.

Where it's recruiting

Kansas

Lenexa

Texas

San Antonio

Source: ClinicalTrials.gov · NCT07767175 · last updated 2026-09-04